Cardiovascular impact of the national program of publicly-funded access to dapagliflozin in Brazil
There was an important change (reduction) in the trends of adverse CV outcomes following the implementation of a national program of publicly-funded access to dapagliflozin. These data highlight that public health measures that improve affordability of medications can significantly impact mortality rates at a population level.
Authors
- Cristiane Bauermann Leitão (ORCID: https://orcid.org/0000-0002-2106-309X)
- Caroline K. Kramer (ORCID: https://orcid.org/0000-0003-1064-0100)
- Fernando Gerchman (ORCID: https://orcid.org/0000-0001-5873-9498)
- Moira K. Kapral (ORCID: https://orcid.org/0000-0002-3444-9928)
- Ravi Retnakaran (ORCID: https://orcid.org/0000-0003-1989-027X)
- Gabriella Richter da Natividade (ORCID: https://orcid.org/0000-0002-2811-3619)
Institutions
- Mount Sinai Hospital (CA)
- Universidade Federal do Rio Grande do Sul (BR)
- University of Toronto (CA)
- Lunenfeld-Tanenbaum Research Institute (CA)
- Hospital de Clínicas de Porto Alegre (BR)
- Public Health Ontario (CA)
Publication Details
- Journal
- Public Health
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1016/j.puhe.2025.106039
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00